INTRODUCTION {#sec1-1}
============

Periodontal tissues represent a unique system, where epithelial, non-mineralized, and mineralized connective tissues exist in harmony. This integrity is essential in providing an effective barrier against microbial invasion and preventing the destruction of the underlying periodontal tissues by bacterial toxins and enzymes. The integrity, however, is lost during chronic inflammation associated with periodontal disease leading to detrimental effects upon the extracellular matrix components of underlying periodontal tissues, including collagens, proteoglycans, and glycosaminoglycans.

Non-surgical mechanical therapy is the cornerstone of periodontal treatment. However, increasing pocket depth and complicating anatomical factors limit the effectiveness of scaling and root planing (SRP), thereby compromising the results. In addition to the better-known antimicrobials and biomaterials, there are number of substances which are less well known and less used at present, and at the same time, have the potential to augment results of periodontal therapy. One such molecule is 'Hyaluronic acid'.

Hyaluronic acid is a polysaccharide present in the connective tissue of vertebrates, a polymer of glucoronic acid and N-acetyglucosylamine, and is a member of glycosamine family with a high molecular weight. Hyaluronic acid (Hyaluronan) is an indispensable component of intact, healthy gingiva, and oral mucosal tissue \[[Figure 1](#F1){ref-type="fig"}\]. It has many properties that make it a potentially ideal molecule for assisting wound healing by inducing early granulation tissue formation, inhibiting inflammation, promoting epithelial turnover and also connective tissue angiogenesis.\[[@ref1]\]
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The application of exogenous hyaluronic acid and hyaluronan based biomaterials has been successful in manipulating and accelerating wound healing process in a number of medical disciplines, as evident in ophthalmology, dermatology, and rheumatology.\[[@ref2]\] Hyaluronan is also a key component of chronic wounds during the series of stages associated with the wound healing process in both mineralized and non-mineralized periodontal tissues. The wound tissue in the early inflammatory phase of repair is rich in hyaluronan, originating from extracellular matrix cells (keratinocytes and fibroblasts in gingiva and periodontal ligament, cementoblasts in cementum, and osteoblasts in alveolar bone) within inflamed sites, or derived from the vascular blood supply to the wound site.

Hyaluronan has numerous roles in these initial inflammatory stages, such as the provision of a structural framework, via the interaction of hyaluronan with the fibrin clot, which modulates host inflammatory and extracellular matrix cell infiltration into the wound site. Hyaluronan also induces the production of a series of polypeptides molecules (pro-inflammatory cytokines) by fibroblasts, keratinocytes, cementoblasts, and osteoblasts, which promote the inflammatory response and consequently stimulates hyaluronan synthesis by blood vessel endothelial cell.

Hyaluronan is further involved in the activation of inflammatory cells, such as polymorphonuclear leukocytes and macrophage functions, including their migration to the wound site, adherence at the wound site, phagocytosis and killing of invading microbial pathogens in order to counteract the colonization and proliferation of anaerobic pathogenic bacteria in the gingival crevice and adjacent periodontal tissues. In a somewhat contradictory role, however, hyaluronan can regulate the inflammatory response via the scavenging of inflammatory cell derived reactive oxygen species, which may contribute to the stabilization of the granulation tissue matrix.

Furthermore, hyaluronan may indirectly act in moderating inflammation and stabilize the granulation tissue by preventing inflammatory cell-derived enzymes (serine proteinases) degrading the extracellular matrix proteins, as healing progresses. The hyaluronan content of non-mineralized chronic wounds is further elevated transiently during the subsequent formation of granulation tissue and in the reestablishment of the epithelium due to an increase in hyaluronan synthesis by fibroblasts and keratinocytes.

In mineralized periodontal tissues such as alveolar bone, the granulation tissue phase is gradually replaced by a provisional mineralized callus. During such stages, hyaluronan contributes to a variety of cellular functions, such as the promotion of extracellular matrix cell migration into the wound matrix, cell proliferation, and granulation tissue organization. Such events allow the reattachment of the basal layer of the gingival epithelium to the basal lamina and the full maturation of mineralized tissues resulting in the reformation of a junction at the tooth interface.

Later in the granulation phase, hyaluronan synthesis ceases, and existing hyaluronan is depolymerized by host enzymes (hyaluronidases) resulting in the formation of lower molecular weight hyaluronan molecules and an alteration in the composition of the granulation tissue. Low molecular weight hyaluronan fragments formed following hyaluronidase activity have been demonstrated to promote blood vessel formation (angiogenesis) within the wound, although the precise mechanism of action is unknown.

Hyaluronan synthesis contributes to local foci of tissue hydration, which is important during cell proliferation and migration. These local foci of tissue hydration weaken cell attachment to the extra cellular matrix allowing temporary detachment to facilitate cell migration and division. In inflammation, hyaluronan has a moderating effect through free radical scavenging (Presti *et al* 1994) as well as the exclusion of tissue degrading enzymes such as metalloproteinase (Fraser *et al* 1996). All these properties along with the release of cytokines when hyaluronan binds to its specific receptor CD-44 explains Hyaluronan\'s key role in the healing process. Thus, it is plausible that hyaluronan administration to periodontal sites could achieve comparable benefits in periodontal healing; hence aiding in treatment of periodontal diseases.\[[@ref1]\]

Though HA is mostly advocated in dentistry for topical application, some recent studies were done on hyaluronan as biomaterials assisting regeneration. A study was done to demonstrate the osteoinductive effect of esterified low molecular weight HA preparation in the treatment of infra bony defects. It was used as a co-adjuvant with autologus bone for grafting procedure. At 9 months from the procedure, the dental parameters were virtually stable with a mean CAL gain of 2.6 mm. Radiographic evaluation after 24 months showed defect fill. This Hyaloss^®^ matrix at room temperature forms a biodegradable, biocompatible gel that can be adapted by the operator to the desired consistency. In fact, the Hyaloss^®^ matrix has a dual function: on one hand, its physiochemical properties facilitate the application of bone graft in the defect site, and on the other hand, it creates an environment with a rich content of HA.\[[@ref3]\]

Another case report demonstrated the use of HA as tissue engineering scaffold. Here, a three-dimensional scaffold consisting of the hyaluronan-based biomaterial HYAFF^®^ was utilized in gingival augmentation procedure. This technique allowed the growth of biopsy-derived gingival fibroblasts in tissue culture within the hyaluronan based biomaterial, followed by the application of the fibroblast-containing biomaterial into a surgical flap above the periosteum. The gingival tissue was subsequently observed to undergo sequential healing and improved gingival attachment, including granulation tissue formation, HYAFF® degradation, re-epithelialization, and angiogenesis.\[[@ref4]\]

Another hyaluronan-based biomaterial, cross-linked hyaluronan has recently been used as a carrier of the recombinant bone-regenerating extracellular matrix component, bone morphogenic protein-2 (BMP-2). The incorporation of BMP-2 into cross-linked hyaluronan has demonstrated significant high-density bone induction. Furthermore, the cross-linked hyaluronan has been suggested to enhance bone regeneration by the protection of BMP-2 from enzymatic degradation, by preventing periodonto-pathogen proliferation, by enhancing cell migration and proliferation at the defect site, and by promoting angiogenesis.\[[@ref5]\]

More recently, a topically applied anti-inflammatory product based on hyaluronic acid has been made commercially available. The present study was a randomized controlled, parallel design study conducted to evaluate the clinical and histological outcomes of subgingival application of 0.2% hyaluronic acid gel (GENGIGEL^®^ Gel, RICERFARMA) \[[Figure 2](#F2){ref-type="fig"}\] along with a single episode of SRP in patients with moderate and advanced periodontitis.
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MATERIALS AND METHODS {#sec1-2}
=====================

This randomized, controlled, parallel design study was conducted on patients attending the Department of Periodontics, V.S. Dental College and Hospital, Bangalore, between 7^th^ September 2008 and 20^th^ October 2009. Twenty six chronic periodontitis patients providing a total of 120 sites were selected. A written informed consent was obtained from all patients prior to their participation in this study. Institutional review board approved the study protocol.

Inclusion criteria for the study were patients with pocket depths ≥5 mm, adequate attached gingiva, and age range between 25 to 55 years. The exclusion criteria included patients with poor systemic health like uncontrolled diabetes, hypertension, osteoporosis, collagen disorders etc. This was ensured by taking thorough patient\'s medical history and by doing general as well as oral examination. The patients who were on and expected to be taking antibiotics and anti inflammatory drugs within the duration of the study were not included.

Clinical parameters such as Gingival index (GI), Bleeding index (BI), Probing Pocket Depth (PPD), and Relative Attachment Level (RAL) were recorded at baseline (0 day), 4^th^, 6^th^, and 12^th^ week. At the time of baseline examination, no significant differences were observed in GI, BI, and PPD in the test and control group allowing the assumption of homogeneity of the patient population.

At first visit, clinical parameters were assessed and full moth supragingival scaling was done. Then SRP was done for selected sites. SRP was accomplished by use of a combination of ultrasonic scalers and curettes until a hard smooth surface was reached as determined by an explorer (No. 23 explorer).\[[@ref6]\] The sites were then randomized into control and experimental sites such that both the groups had 60 sites each.

Experimental sites additionally received 1 ml of 0.2% HA gel application \[[Figure 3](#F3){ref-type="fig"}\] subgingivally, till the depth of pocket. This was done by taking the gel into a syringe and applying it with wide gauge needle assuring that the tip reaches the depth of the pocket. No binding or sealing agent was used as hyaluronan macromolecule has shown to act as either a mucoadhesive and retain the drug at its site of action/absorption or to modify the *in vivo* release/absorption rate of the therapeutic agent it is used with.\[[@ref7]\] It has also exhibited bioadhesion resulting in increased bioavailability in mucosa owing to its viscoelastic property.\[[@ref8]\]
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The gel contains hyaluronan, xylitol, and excipients. The hyaluronic acid in gengigel^®^ is produced by a non-animal derived biotechnological process which is patented. Hyaluronan gel is tasteless, odorless, and colorless. It is easy to apply, does not stain teeth, and is not inactivated by sodium lauryl sulphate. No undesirable side effects associated with medication were reported by the patients.

HA gel application subgingivally was repeated at experimental sites at the end of 1^st^, 2^nd^, and 3^rd^ week as patient\'s dexterity and compliance is less than satisfactory when it comes to 'at home subgingival delivery of drug′. At the 4^th^ week recall, clinical parameters were assessed and recorded at all the sites. A marginal gingival biopsy of the size ranging from 1mm to 1.5mm maintaining the scalloped contour was obtained from experimental and control sites, providing tissue for histologic examinations. Marginal gingiva of the tooth with pseudo pocket, residual deep pocket, or inflamed gingiva was the preferred site for biopsy.

The specimens obtained were embedded in paraffin blocks, sectioned, and stained with hematoxylin and eosin stain for examination under light microscope. The grading of the inflammatory infiltrate was established by randomly selecting and counting 10 fields of lamina propria at ×400 magnification. Inflammatory infiltrate was graded in the following manner: "Absent", when none of the 10 fields show inflammatory cells; "Slight", when at least 5 fields contain inflammatory cells that occupy \<50% of the field; "Moderate", when at least 5 fields show inflammatory cells that occupy \>50% of the field; and "Intense", when all 10 fields evaluated show inflammatory cells that occupy \>90% of the field\[[@ref9]\] \[Figures [4](#F4){ref-type="fig"}--[7](#F7){ref-type="fig"}\].
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All patients providing the test and control sites were recalled at 6^th^ and 12^th^ week for the assessment of clinical parameters at the remaining sites \[Figures [8](#F8){ref-type="fig"}--[11](#F11){ref-type="fig"}\].
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![Clinical parameters at test site at 12^th^ week](JISP-16-184-g011){#F11}

RESULTS {#sec1-3}
=======

There was even distribution of samples according to the age and gender \[[Figure 12](#F12){ref-type="fig"}\]. Data obtained was subjected to appropriate statistical analysis.

The mean GI at control sites at baseline was 2.02±0.07, while at the experimental sites, it was 2.04±0.09. The differences in GI scores between control and experimental sites at the baseline were not statistically significant (*P*\>0.05).
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At the control sites, GI reduced from baseline to 4^th^, 6^th^, and 12^th^ week by an average of 37.11%, 40.20%, and 41.24%, respectively. At the experimental sites, GI reduced from baseline to 4^th^, 6^th^, and 12^th^ week by an average of 47.37%, 54.38%, and 56.14%, respectively. The mean GI at 4^th^ week at control sites was 1.27±0.29, while at experimental sites, it was 1.07±0.23. The differences in GI scores between control and experimental sites were not statistically significant (*P*\>0.05) at this point of time. At 6^th^ week, the mean gingival index at control sites was 1.21±0.26, while at experimental sites, it was 0.93±0.23. Higher mean GI was noticed at control sites as compared to the experimental sites at 6 ^th^ week time interval. The differences between experimental and control sites were found to be statistically significant (*P*\<0.05).

At 12^th^ week, the mean GI at control sites was 1.19±0.24, while at the experimental sites, it was 0.89±0.21. The differences in the GI scores between control and experimental sites were statistically significant (*P*\<0.01) \[Figures [13](#F13){ref-type="fig"} and [14](#F14){ref-type="fig"}\].
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The mean BI at the control sites at baseline was 1.00, while at the experimental sites, it was 1.00. No statistically significant difference was observed between control and experimental sites with respect to BI scores at baseline (*P*\>0.05) \[[Figure 15](#F15){ref-type="fig"}\].
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The BI at control sites reduced on an average by 70.83%, 77.08%, and 79.17%, from baseline to 4^th^ week, 6^th^ week and 12^th^ week, respectively. At experimental sites, the BI reduced on an average by 87.5%, 94.64%, and 98.21%, from baseline to 4^th^, 6^th^, and 12^th^ week, respectively. At 4^th^ week, the mean BI at control sites was 0.29±0.26, while at the experimental sites, it was 0.13±0.16. At 4 weeks time interval, when comparison was made between control and experimental sites, the differences in BI scores were not statistically significant (*P*\>0.05). At 6^th^ week, the mean BI at control sites was 0.23±0.23, while at experimental sites, it was 0.05±0.11 \[[Figure 16](#F16){ref-type="fig"}\]. Higher mean BI was noticed at control sites compared with experimental sites at 6^th^ week time interval, and the difference between the two scores were statistically significant (*P*\<0.05).
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At 12^th^ week, the mean BI at control sites was 0.21±0.21; while at the experimental sites, it was 0.02±0.07. The differences in the BI scores between control and experimental sites were statistically significant (*P*\<0.01).

At baseline, the mean probing pocket depth was 6.42±0.44 at the control sites and 6.57±0.45 at the experimental sites. The differences in PPD values between control and experimental sites were not statistically significant (*P*\>0.05) \[[Figure 17](#F17){ref-type="fig"}\].
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The PPD at control sites reduced from baseline to 4^th^, 6^th^, and 12^th^ week by an average of 13.31%, 20.05%, and 23.05%, respectively. At experimental sites, it reduced from baseline to 4^th^, 6^th^, and 12^th^ week by an average of 17.67%, 23.64%, and 26.63%, respectively. At 4^th^ week, the PPD values reduced to 5.56±0.40 at control sites and 5.41±0.46 at the experimental sites. At 6^th^ week, the PPD values were 5.10±0.33 at control sites and 5.02±0.41 at experimental sites. At 12^th^ week, the PPD further reduced to 4.94±0.26 at control sites and 4.82±0.32 at experimental sites \[[Figure 18](#F18){ref-type="fig"}\]. When comparisons were made between control and experimental sites, higher mean PPD was observed at control sites at 4^th^, 6^th^, and 12^th^ week interval. However, no statistically significant differences were observed in PPD values between experimental and control sites at 4, 6, and at 12 week time interval (*P*\>0.05).
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The mean RAL at the baseline at control sites was 8.56±0.41 and 8.91±0.41 at the experimental sites. Statistically significant differences in the RAL values were observed between control sites and experimental sites at baseline (*P*\<0.05) \[[Figure 19](#F19){ref-type="fig"}\].
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The RAL values at control site reduced by 7.54%, 9.73%, and 11.19%, when compared from baseline to 4^th^, 6^th^, and 12^th^ week. On the other hand, at experimental sites, the RAL values reduced by 10.01%, 13.03%, and 14.23%, when compared from baseline to 4^th^, 6^th^, and 12^th^ week. At 4^th^ week, the mean attachment level at the control sites reduced to 8.02±0.56 and 7.92±0.44 at the experimental sites. At 6^th^ week, the mean attachment level was 7.75±0.54 at control sites and 7.73±0.58 at experimental sites. At 12^th^ week, mean RAL further reduced to 7.64±0.53 at control sites and 7.60±0.59 at experimental sites \[[Figure 20](#F20){ref-type="fig"}\].
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When comparisons were made between control and experimental sites, higher mean RAL was observed at control sites; however, no statistically significant differences were observed in the RAL values of experimental and control sites at 4^th^, 6^th^, and 12^th^ week interval (*P*\>0.05).

To summarize, when all the four clinical parameters at control and experimental sites were subjected to intra group analysis from baseline to 4^th^ week, baseline to 6^th^ week and baseline to 12^th^ week, results showed statistically significant changes in all clinical parameters (*P*=0.05) at all time intervals. Analysis also showed that changes in the clinical parameters from baseline to 4^th^, 6^th^, and 12^th^ week were higher at the experimental sites than at the control sites. On comparing the clinical parameters between experimental and control sites at 4^th^, 6^th^, and 12^th^ week interval, statistically significant differences were observed in GI and BI scores at 6^th^ and 12^th^ week, whereas, differences between PPD and RAL values were not statistically significant.

Histological assessment {#sec2-1}
-----------------------

None of the control or experiment sites showed absent or intense inflammatory infiltrate. About 33.3% of control and 71.4% of experimental sites showed slight inflammatory infiltrate. On the other hand, 66.7% of control and 38.6% of experimental sites showed moderate infiltrate \[[Figure 21](#F21){ref-type="fig"}\]. Thus, the number of sites with lesser degree of inflammatory infiltrate were more at the experimental sites. But no statistically significant association was found between the histological grading and the sites that received HA treatment (*P*\>0.05). Same was true with the control sites too.

![Histological assessment of inflammatory infiltrate](JISP-16-184-g021){#F21}

DISCUSSION {#sec1-4}
==========

Non-surgical mechanical periodontal treatment is the cornerstone of periodontal therapy and the first recommended approach to the control of periodontal infections. Conventional, non-surgical periodontal therapy consists of mechanical supra- and sub-gingival tooth debridement and instructions in self-administered oral health care measures. However, subgingival SRP is a technically demanding procedure and is not always efficient at eradicating all periodontal pathogens and reducing gingival inflammation, especially in pockets greater than 5 mm. It is, therefore, logical that local subgingival application of other chemotherapeutic agents may enhance the clinical and microbial benefits of mechanical debridement.

The effects of HA are molecular weight- and concentration-dependent and is cell-specific. HA levels within extracellular matrix have been shown to promote or inhibit the state of differentiation of several mesenchymal progenitor cell types and to participate directly in cell-cell aggregation events. These matrix-induced effects on cells are in turn supported and directed by a wide variety of HA-binding proteins. Some of these HA-binding proteins interact with HA within the extracellular matrix proper, whereas others interact with HA at the plasma membrane of cells, as cell-surface matrix 'receptors'. Various other biological properties exhibited by hyaluronan are given below.

Matrix structures {#sec2-2}
-----------------

Hyaluronan plays a structural role in cartilage and other tissues. The cartilage proteoglycan, aggrecan, is bound specifically to hyaluronan chains. The aggregates formed have masses in the order of 1×10^8^ daltons and are deposited within the collagen framework.

Water balance {#sec2-3}
-------------

Hyaluronan solutions of concentrations similar to those found in soft connective tissue exhibit interesting physical and chemical properties. Hyaluronan plays role in the homeostasis of the extracellular space. For example, the non ideal osmotic behavior of hyaluronan and similar polymers makes them efficient as osmotic buffers. The osmotic contribution of polysaccharide networks together with their flow resistance gives them a role in the water homeostasis of the tissues.

Steric interactions {#sec2-4}
-------------------

At physiological concentrations, the hyaluronan molecules entangle and form a random network of chains. Such networks interact sterically with other macromolecular components. Hyaluronan excludes other macromolecules, especially large ones that cannot find space in the network. It also retards the diffusion of other substances that cannot penetrate the network. By these properties, hyaluronan and other polysaccharides regulate the distribution and transport of plasma proteins in the tissues.

Lubrication {#sec2-5}
-----------

The extraordinary rheological properties that hyaluronan solutions exhibit (e.g., in synovial fluid) have led to speculations about its role in the lubrication of joints and tissues. Joint fluid and concentrated (0.1-1%) solutions of hyaluronan show visco-elastic behavior and the viscosity is strongly shear-dependent.

Cell proliferation {#sec2-6}
------------------

It is well known from many studies that hyaluronan production is high during cell proliferation. A possible function would be that hyaluronan, growing out from the cell surface, causes a detachment of the cell from its supporting matrix so that it can divide more easily. *In vitro* cell detachment mediated by hyaluronan has been described.

Recognition {#sec2-7}
-----------

In some early studies, it was shown that low concentrations of hyaluronan could aggregate in certain cells such as lymphoma cell lines, virally transformed cell lines, and lung macrophages. This phenomenon is mediated by hyaluronan-binding proteins on the cell surface.\[[@ref2]\]

In this study, to study the clinical effects of hyaluronan in periodontitis, various indices were used. GI provides an assessment of gingival inflammatory status that can be used to compare gingival status at recall visits. Comparison between experimental and control sites showed no statistically significant difference in GI at 4^th^ week time interval, but a statistically significant difference in GI was shown at 6^th^ week and 12^th^ week time interval. A statistically significant reduction in GI was seen in both experimental and control sites at all intervals of time (4^th^, 6^th^, and 12^th^ week), when compared to baseline, indicating that debridement itself results in significant reduction in clinical signs of periodontal disease.

This may be because supra and sub-gingival calculus removal results in reduction of microbial load and thereby the endotoxins. This results in reduced severity of inflammatory infiltrate in the periodontal soft tissues, thereby providing conducive environment for diseased gingival tissues to heal. The change being higher in the experimental group signifies additional beneficial effect of HA gel in healing.

Bleeding on probing provides an objective, easily reproducible assessment of gingival status. It is extremely useful for detecting early inflammatory changes and the presence of inflammatory lesions located at the base of the pocket, an area which is usually inaccessible to visual examination.\[[@ref10]\] When compared with baseline, a statistically significant reduction in BI scores were observed in both experimental and control sites at all points of time during the study. Comparison between experimental and control sites showed a statistically significant difference in BI scores at 6^th^ week and 12^th^ week time interval, but not at the 4^th^ week interval. The improvement is possibly due to the beneficial effects of SRP, which helps sulcular epithelium regain its structural integrity and optimum thickness. The blood vessels attain normal tonus as inflammatory mediators diminish. HA gel is additionally known to enhance formation of extracellular connective tissue matrix leading to non-inflamed and healthy periodontal tissue that is less susceptible to bleeding on probing. These results are in agreement with the previously done studies by Pomowski *et al*,\[[@ref11]\] and Pistorius *et al*.,\[[@ref12]\]

Periodontal pockets are pathognomic signs of periodontal disease and therefore attain critical status in diagnosis of periodontitis. When compared from baseline to 4^th^, 6^th^, and 12^th^ week, a statistically significant reduction in probing pocket depth was observed at both experimental and control sites. No statistically significant differences were observed in PPD values between control and experimental sites at 4, 6, and at 12 weeks time interval (*P*\>0.05). Higher PPD was observed at control sites compared with experimental sites at 4, 6, and 12 weeks time interval. Changes in PPD and RAL may be attributed to the reduction in gingival inflammation and resolution in inflammatory exudates along with the formation of new collagen fibers. Favorable changes in PPD and RAL values at the experimental sites may be attributed to the beneficial effect of HA gel.

Thus, in terms of clinical parameters, when comparisons were made between experimental and control sites, a significant improvement was found in GI and BI scores at experimental sites, while changes in PPD and RAL were not statistically significant. This is in agreement with earlier study done by Xui *et al*.,\[[@ref13]\]

However, intra group changes in GI, BI, PPD, and RAL at different time intervals were higher at experimental sites compared with control sites, indicating the ability of hyaluronan in preventing progression of lesion and maintaining the pocket in an inactive state.

About 33.3% of control and 71.4% of experimental sites showed slight inflammatory infiltrate. On the other hand, 66.7% of control and 38.6% of experimental sites showed moderate infiltrate. Thus, majority of experimental sites showed lesser degree of inflammatory infiltrate as compared with the control sites. This may be due to the additional beneficial effect of hyaluronic acid when used as an adjunct to SRP. This is in accordance with a double-blind clinical trial, which concluded that high molecular-weight HA gel reduces cell proliferation in epithelial cells, fibroblasts, and lymphocytes abates the inflammatory process, and improves the periodontal lesion in patients with chronic periodontitis.\[[@ref14]\] However, in our study, no statistically significant association was found between the histological grading and the sites that received HA treatment (*P*\>0.05). Same was true with the control group too.

Different mechanisms have been proposed to explain the effect of HA on the inflammatory process. Cortivo *et al* (1986) considered that HA produces a physical barrier against bacteria and their products in extracellular matrix. Haapasalo *et al* (1996) demonstrated that chemotrypsin induced binding of HA to *T. denticola*, preventing its destructive action on the periodontium. More recently, HA has been shown to be the main ligand of the CD44 receptor (Goodson *et al*, 1999). Isoforms of the CD44 receptor are involved in the initial binding of leukocytes to endothelial cells activated by inflammatory processes.\[[@ref9]\]

The present study was aimed to evaluate the effect of hyaluronan in periodontitis patients. The results at both control and experimental sites were significant when compared to baseline; this reinforces the already established importance of SRP in non surgical periodontal therapy. When comparisons were made between the control and experimental sites, results were significant only in terms of gingival parameters, but not that of periodontal parameters.

The reasons for the above may be numerous, hyaluronan levels used in this study were below the optimum levels due to lesser frequency of subgingival HA gel application and that was due to inability of the patients to apply it subgingivally themselves. Secondly, the gel was placed with the help of syringe, and thus, it was uncertain that the gel reached the entire area affected by disease, especially the base of the pocket. Thirdly, the absorption kinetics of this gel formulation is unknown in terms of its physical stability for a sufficiently long period of time in the periodontal pocket though it exhibits viscoelastic properties in other body tissues. Lastly, HA gel is also not yet known to bind and penetrate the periodontal tissues, whereas it has been shown to be bio-adhesive and retentive in nasal mucosa and ocular tissue, respectively.\[[@ref7]\]

So, it can be inferred that hyaluronan enhanced the results of SRP by improving the gingival parameters. Additionally, it also helped in preventing progression of periodontal lesion. In patients with periodontitis, more favorable results may be expected if hyaluronan is used in conjunction with surgical periodontal therapy.
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